Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck : Submits Applications for Licensure of V114, the Company's Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults

11/24/2020 | 08:46am EST

KENILWORTH - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the company has submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for licensure of V114, Merck's investigational 15-valent pneumococcal conjugate vaccine, for use in adults 18 years of age and older.

The company awaits acceptance of the submissions by the U.S. and European regulatory authorities.

'For more than a century, Merck inventors have developed vaccines that help tackle some of society's biggest public health challenges, and that heritage is reflected today in our pneumococcal vaccine portfolio,' said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. 'These submissions for V114 help bring us closer to offering more options to help protect against pneumococcal disease.'

The regulatory applications for licensure of V114 include results from Phase 2 and Phase 3 clinical studies in a variety of adult populations, including healthy adults and those at increased risk, such as adults with chronic medical conditions, adults with HIV, and those 65 years of age and older.

About V114

V114 is Merck's investigational 15-valent pneumococcal conjugate vaccine candidate for the prevention of pneumococcal disease in adults and children. V114 consists of pneumococcal polysaccharides from 15 serotypes conjugated to a CRM197 carrier protein and includes serotypes 22F and 33F, which are commonly associated with invasive pneumococcal disease in older adults worldwide and are not contained in the pneumococcal conjugate vaccine currently licensed for use in adults. An overview of the late-stage development program for V114 is available here.

V114 previously received Breakthrough Therapy Designation from the FDA for the prevention of invasive pneumococcal disease in pediatric patients 6 weeks to 18 years of age and adults 18 years of age and older.

Merck's Commitment to Infectious Diseases

For more than 100 years, Merck has contributed to the discovery and development of novel medicines and vaccines to combat infectious diseases. In addition to a combined portfolio of vaccines and antibacterial, antiviral and antifungal medicines, Merck has multiple programs that span discovery through late-stage development.

About Merck

For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases as we aspire to be the premier research-intensive biopharmaceutical company in the world.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's 2019 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

Contact:

Pamela Eisele

Tel: (267) 305-3558

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about MERCK & CO., INC.
01/21MERCK : Announces U.S. FDA Approval of VERQUVO
AQ
01/21MERCK : Bayer - U.S. FDA approves vericiguat for patients with symptomatic chron..
AQ
01/20MERCK : Canada and MaRS Team Up to Launch Lung Cancer Innovation Challenge
AQ
01/20MERCK : Gets FDA Approval for Verquvo
DJ
01/20MERCK : Receives US FDA Approval of Heart Failure Treatment Verquvo
MT
01/20MERCK : Announces U.S. FDA Approval of VERQUVO® (vericiguat)
BU
01/20UPDATE : DeepMatter Jumps 18% on Multi-Year Data Licensing Contract with Merck's..
MT
01/20DeepMatter Lands Multi-Year Data Licensing Contract With Merck's Life Science..
MT
01/14Philips Partners with Merck to Develop Digital Systems for Fertility Treatmen..
MT
01/13Ligand Pharmaceuticals to Receive $1.5 Million Milestone Payment From Merck
MT
More news
Financials (USD)
Sales 2020 48 199 M - -
Net income 2020 12 145 M - -
Net Debt 2020 15 159 M - -
P/E ratio 2020 17,1x
Yield 2020 3,02%
Capitalization 205 B 205 B -
EV / Sales 2020 4,57x
EV / Sales 2021 4,20x
Nbr of Employees 71 000
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Average target price 96,95 $
Last Close Price 80,98 $
Spread / Highest target 32,1%
Spread / Average Target 19,7%
Spread / Lowest Target 4,96%
EPS Revisions
Managers and Directors
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-1.00%204 882
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
PFIZER INC.-0.71%203 159
ABBVIE INC.3.46%195 720